Published online before print April 24, 2008, doi: 10.1161/STROKEAHA.107.508754
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Stroke. 2008;39:2122.)
© 2008 American Heart Association, Inc.
Original Contributions |
Oxyhemoglobin-Induced Expression of R-Type Ca2+ Channels in Cerebral Arteries
From the Department of Surgery, Division of Neurosurgery (T.E.L., B.I.T., G.C.W.) and the Department of Pharmacology (K.M., M.B.-M., G.C.W.), University of Vermont College of Medicine, Burlington.
Correspondence to Dr George C. Wellman, Department of Pharmacology, University of Vermont College of Medicine, 86 Beaumont Ave, Burlington, VT 05405. E-mail George.Wellman{at}uvm.edu
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Background and Purpose— Cerebral vasospasm after subarachnoid hemorrhage (SAH) is a major contributor to mortality and morbidity after aneurysm rupture. Recently, R-type voltage-dependent Ca2+ channel (VDCC) expression has been associated with increased cerebral artery constriction in a rabbit model of SAH. The goal of the present study was to examine whether the blood component oxyhemoglobin (oxyHb) can mimic the ability of SAH to cause R-type VDCC expression in the cerebral vasculature.
Methods— Rabbit cerebral arteries were organ cultured in serum-free media for up to 5 days in the presence or absence of purified oxyHb (10 µmol/L). Diameter changes in response to diltiazem, (L-type VDCC antagonist) and SNX-482 (R-type VDCC antagonist) were recorded at day 1, 3, or 5 in arteries constricted by elevated extracellular potassium. RT-PCR was performed on RNA extracted from arteries cultured for 5 days (±oxyHb) to assess VDCC expression.
Results— After 5 days, oxyHb-treated arteries were less sensitive and partially resistant to diltiazem compared to similar arteries organ cultured in the absence of oxyHb. Further, SNX-482 dilated arteries organ cultured for 5 days in the presence, but not in the absence, of oxyHb. RT-PCR revealed that oxyHb treated arteries expressed R-type VDCCs (CaV 2.3) in addition to L-type VDCCs (CaV 1.2), whereas untreated arteries expressed only CaV 1.2.
Conclusions— These results demonstrate that oxyhemoglobin exposure for 5 days induces the expression of CaV 2.3 in cerebral arteries. We propose that oxyhemoglobin contributes to enhanced cerebral artery constriction after SAH via the emergence of R-type VDCCs.
Key Words: calcium channels • cerebral arteries • subarachnoid hemorrhage • vasospasm • vascular smooth muscle
|
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Oxyhemoglobin (oxyHb) has been implicated in the development of cerebral vasospasm and the associated delayed neurological deficits frequently encountered after aneurysmal subarachnoid hemorrhage (SAH). For example, the peak in free oxyHb concentrations in the cerebral spinal fluid of SAH patients, attributable to lysis of red blood cells, correlates with the onset of cerebral vasospasm after aneurysm rupture.1 Further, in vivo application of oxyHb into the subarachnoid space can mimic the effect of whole blood to induce cerebral vasospasm.2 Although evidence suggests oxyHb contributes to the development of SAH-induced vasospasm, the mechanisms involved in this phenomenon are less clear.
Acute application of oxyHb constricts cerebral arteries via a number of mechanisms including suppression of K+ channel activity, enhanced calcium entry, and increased activity of protein kinase C and Rho kinase.3–9 Currently, it is uncertain whether altered gene expression may also contribute to the ability of oxyHb to decrease cerebral artery diameter. Our laboratory has recently shown expression of R-type VDCCs, encoded by the gene CaV 2.3, in small diameter cerebral arteries in a rabbit model of SAH.10 The emergence of R-type VDCCs in cerebral artery myocytes, combined with existing L-type VDCCs, would promote elevated intracellular free Ca2+ concentration ([Ca2+]i) and ultimately increased cerebral artery constriction.
The objective of the present study was to examine whether purified oxyHb mimics SAH to induce CaV 2.3 expression in the cerebral vasculature. Here, we report the emergence of R-type VDCCs in cerebral arteries from healthy rabbits organ cultured in the presence of purified oxyHb for a period of 5 days. Further, our data suggest that L-type VDCCs in cerebral arteries become less sensitive to antagonists such as diltiazem after 5-day exposure to oxyHb. These findings are consistent with a role of oxyHb-induced R-type VDCC expression in enhanced constriction of small diameter cerebral arteries after SAH.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
All protocols were conducted in accordance with the Guidelines for the Care and Use of Laboratory Animals (NIH) and approved by the Institutional Animal Care and Use Committee of the University of Vermont. New Zealand White rabbits (male, 3.0 to 3.5 kg) were euthanized by exsanguination under deep pentobarbital anesthesia (IV; 60 mg/kg). Cerebral arteries were dissected in ice cold MOPS solution containing 1% BSA with the following composition (in mmol/L): 145 NaCl, 5 KCl, 1 MgSO4, 2.5 CaCl2, 1 KH2PO4, 0.02 EDTA, 2 pyruvate, 5 glucose, 3 3-(N-morpholino) propanesulfonic acid (MOPS), pH 7.4.
Organ Culture of Cerebral Arteries
Once blood was flushed from the lumen, anterior and posterior cerebral arteries were transferred into serum free Dulbecco modified Eagle medium (DMEM)/F12 supplemented with penicillin (50 U/mL) and streptomycin (50 µg/mL) and placed in an incubator at 37°C with 5% CO2 and 97% humidity. Arteries were cultured for up to 5 days in the presence or absence of purified hemoglobin Ao (oxy form; 10 µmol/L, Hemosol Inc; oxyHb). Culture medium was changed twice daily to maintain oxyHb levels, as our spectrophotometric studies indicate that oxyHb concentrations decreased approximately 20% after 8 hours in organ culture (data not shown). A concentration of 10 µmol/L oxyHb was chosen to approximate extravascular levels of this compound reported near cerebral arteries after SAH.1 Preliminary studies were also performed using arteries organ cultured with a higher concentration (100 µmol/L) of oxyHb. However, we observed a dramatic decrease in the viability of arteries organ cultured with 100 µmol/L oxyHb for a period of 5 days (5 of 5 arteries from 3 different animals).
Diameter Measurements in Isolated Arteries
Isolated arteries were cannulated in a 5-mL myograph chamber (Living Systems Instruments) and perfused with aerated physiological saline solution (PSS) with the following composition (in mmol/L): 118.5 NaCl, 4.7 KCl, 24 NaHCO3, 1.18 KH2PO4, 1.6 CaCl2, 1.2 MgCl2, 0.023 EDTA, and 11 glucose, pH 7.4) at 37°C, as previously described.11 Arteries were discarded if an initial constriction representing less than a 40% decrease in diameter to 60 mmol/L K+ PSS (iso-osmotic replacement of NaCl with KCl) was observed. To explore VDCC function, isolated arteries were constricted by increasing extracellular K+ from 6 mmol/L to 60 mmol/L, shifting the K+ equilibrium potential (EK) from approximately –85 mV to approximately –20 mV. In cerebral artery myocytes, the membrane potential depolarization accompanying this positive shift in EK leads to an increase in the open-state probability of VDCCs, an increase in the concentration of free intracellular Ca2+ ([Ca2+]i), and vasoconstriction.12,13 To selectively study VDCC function, arteries were held at a relatively low intravascular pressure (20 mm Hg) to minimize activation of mechanosensitive cation channels and other cell signaling pathways such as protein kinase C.14 Cumulative concentration-response curves to the L-type VDCC blocker diltiazem15 were obtained from arteries constricted with 60 mmol/L K+ PSS at an intravascular pressure of 20 mm Hg. Dilations to the R-type VDCC blocker SNX-482 (200 nmol/L)16 were obtained from arteries constricted with 60 mmol/L K+ PSS in the presence and absence of diltiazem. Responses to the endothelium-dependent vasodilator acetylcholine and the nitrovasodilator sodium nitroprusside were examined in arteries constricted by a combination of histamine (30 µmol/L) and serotonin (30 µmol/L) at an intravascular pressure of 60 mm Hg. Oxyhemoglobin was not included in the PSS during diameter measurements in isolated cerebral arteries.
RNA Isolation and RT-PCR
Total RNA was extracted from freshly isolated and organ cultured cerebral arteries and brain using RNeasy Micro kit (QIAGEN). cDNA was synthesized by Omniscript reverse transcriptase (QIAGEN) using 250 ng of total RNA. Reactions were also performed in the absence of reverse transcriptase as a negative control, using an equal amount of total RNA. A unique coding region of the R-type VDCC 
1 subunit (1E; CaV 2.3 GenBank Accession # X67855) was amplified using the following set of primers: sense nucleotides 6562 to 6580 (5'-GAGCAGCGACAACACCTAC-3') and antisense nucleotides 6996 to 6978 (5'-GCTGGTGGAGAGAAGTTGC-3'). Semiquantitative RT-PCR analysis was performed by comparing band intensities of arteries organ cultured in the absence and presence of oxyHb when equivalent amounts of cDNA were used for each preparation as determined by GAPDH PCR amplification. To further verify expression of CaV 2.3, nested PCR was used with the following sets of primers: forward primer 5'-ACCCCTCGTCCTGTCCTCAC-3' (3586–3605) and reverse primer 5'-TGCTCTCGGTGGTGACCTTG-3' (3773–3754) for the 1st round PCR; 5'-CGAGGGTGTGGGGAAAGAG-3' (3607–3625) and 5'-CGGTGGTGACCTTGTCTGTG-3' (3767–3748) for the 2nd round PCR. The amplified DNA was extracted from gel bands and sequenced to confirm PCR products.
Statistical Analysis
Data are presented as mean±SEM. Statistical significance was considered at the level of P<0.05 (*) or P<0.01 (**) using Student t test for comparisons between 2 groups or analysis of variance followed by Student-Newman-Keuls test for pairwise multiple comparisons.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Five-Day Oxyhemoglobin Exposure Reduces the Efficacy of the L-Type VDCC Blocker Diltiazem to Dilate Cerebral Arteries
Our initial goal was to examine the impact of 1- to 5-day oxyHb exposure on VDCC function in small diameter cerebral arteries. Increasing extracellular K+ to 60 mmol/L caused freshly isolated cerebral arteries to constrict by 113±12 µm, representing a 59% decrease in diameter (n=5). In the presence of 60 mmol/L K+, the L-type VDCC blocker diltiazem evoked a concentration-dependent dilation of freshly isolated cerebral arteries, causing a maximum dilation of 98.8±0.4% at a concentration of 1 mmol/L (Figure 1a). To explore the influence of oxyHb on VDCC function, cerebral arteries were placed in serum-free organ culture media in the presence or absence of purified oxyHb (10 µmol/L) for a period of 1 to 5 days. After organ culture, arteries were removed from the media, placed in PSS (in the absence of oxyHb), and canulated for in vitro diameter measurements. After a 30-minute equilibration period, in vitro arterial diameters in PSS were not significantly different between organ cultured and freshly isolated arteries (Table). As with freshly isolated arteries, diltiazem (1 mmol/L) fully dilated arteries organ cultured for 24 or 72 hours (±oxyHb) that were constricted with 60 mmol/L extracellular K+ (Figure 1a and 1b). The IC50 values for diltiazem-induced dilation were not significantly different (approximately 1 µmol/L, Table) in freshly isolated arteries and arteries organ cultured for 24 or 72 hours (±oxyHb). However, after 5 days of organ culture, a marked difference emerged between arteries maintained in the presence and absence of oxyHb. K+-induced constrictions from arteries organ cultured for 5 days in the presence of oxyHb were significantly less sensitive to diltiazem as evidenced by a more than 10-fold increase in the IC50 value (16.9±6.9 µmol/L). Further, approximately 20% of the K+-induced constriction in these arteries was resistant to 1 mmol/L diltiazem, a concentration nearly 1000-fold higher than the IC50 for freshly isolated arteries (Figure 1c).
|
|
We next examined whether organ culture of arteries for 5 days affected responses to the endothelium-dependent vasodilator acetylcholine (Ach) or the endothelium-independent nitrovasodilator sodium nitroprusside (SNP). As Ach and SNP may act in part through K+ channel activation,17 arteries were constricted with a combination of histamine and serotonin, rather than with 60 mmol/L K+. Ach-induced dilations were significantly reduced in arteries organ cultured for 5 days compared to freshly isolated arteries (Figure 2b). However, no significant differences were observed in Ach-induced dilations in arteries cultured for 5 days in the absence compared to the presence of oxyHb. In contrast to Ach responses, SNP-induced dilations were similar in freshly isolated arteries and arteries organ cultured in the absence and presence of oxyHb (Figure 2c). Thus, although organ culture of arteries may lead to a decrease in endothelial cell viability, inclusion of oxyHb in the organ culture media did not per se alter Ach-induced vasodilation. Further, responses to the exogenous nitrovasodilator, SNP, were not altered by organ culture or oxyHb treatment. These data suggest that the decreased efficacy of diltiazem to dilate arteries organ cultured in the presence of oxyHb reflects a selective and fundamental change in VDCCs of cerebral artery myocytes.
|
The R-Type VDCC Blocker SNX-482 Dilates Cerebral Arteries After 5-Day Exposure to Oxyhemoglobin
The above data demonstrate that K+-induced constriction of cerebral arteries exposed to oxyHb for 5 days is partially resistant to the L-type VDCC blocker diltiazem. We have previously reported a similar phenomenon attributable to the emergence of R-type VDCCs in cerebral arteries obtained from a rabbit model of subarachnoid hemorrhage.10 We next examined whether diltiazem-resistant constrictions observed after 5-day oxyHb treatment could be reversed by SNX-482, a blocker of R-type VDCCs.16 In arteries treated with oxyHb for a period of 5 days, diltiazem (1 mmol/L) dilated K+-constricted arteries by 83.2±3.1%, and subsequent addition of SNX-482 (200 nmol/L) caused a further dilation of these arteries to their maximum diameter. Thus, the combination of diltiazem and SNX-482 caused a complete reversal of K+-induced constriction in oxyHb-treated arteries, similar to the effects of diltiazem alone in untreated organ cultured arteries (Figure 3a). In the absence of diltiazem, SNX-482 significantly dilated arteries treated with oxyHb for 5 days (33.5±4.7 µm, n=4), but did not significantly alter the diameter of arteries organ cultured for a similar period in the absence of oxyHb (Figure 3b). As predicted, SNX-482 did not dilate arteries exposed to oxyHb for shorter periods of time (1 or 3 days, n=3; data not shown). These results indicate the functional presence of R-type VDCCs in small diameter cerebral arteries treated with oxyHb for 5 days whereas arteries organ cultured for a similar period in the absence of oxyHb have a single population of diltiazem-sensitive L-type VDCCs.
|
Oxyhemoglobin Increases Expression of R-Type VDCCs in Cerebral Arteries
To further examine the ability of oxyHb to increase R-type VDCCs in cerebral arteries, RT-PCR was used to determine mRNA levels of CaV 2.3, the gene encoding the pore-forming 1 subunit of R-type VDCCs. In the absence of oxyHb, CaV 2.3 mRNA was not detected in arteries cultured for 5 days (n=5). However, after 5-day treatment with oxyHb, CaV 2.3 mRNA was observed in 3 of 5 preparations, although the intensities of these bands were relatively faint (Figure 4a). RT-PCR studies were repeated on arteries obtained from an additional 6 animals. In this second RT-PCR series, semiquantitative analysis revealed a significant increase in CaV 2.3 mRNA levels in samples organ cultured in the presence compared to the absence of oxyHb (Figure 4b). To confirm the selective expression of CaV 2.3 in arteries cultured in the presence of oxyHb, we performed nested PCR. Nested PCR is a highly sensitive method to detect low levels of gene expression by using 2 rounds of PCR. Here, the first round PCR product, as amplified using primers targeting a region that is unique to CaV 2.3, was used as a template for the second round of PCR. Using nested PCR, expression of R-type Ca2+ channels after 5-day treatment with oxyHb was clearly seen in 5 of 5 preparations examined (Figure 4b). In arteries organ cultured in the absence of oxyHb, a PCR band corresponding to CaV 2.3 was observed in 1 of 5 samples. DNA analysis confirmed that the sequence of these bands matched the CaV 2.3 sequence in published database (GenBank Accession number X 67855). These results demonstrate that organ culture of arteries with oxyHb induces R-type VDCC gene expression.
|
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Here we provide evidence that oxyhemoglobin can induce R-type VDCC expression in small diameter cerebral arteries. We report that arteries organ cultured for a period of 5 days in the presence of oxyHb exhibit constrictions that were partially resistant to the L-type VDCC antagonist, diltiazem. This diltiazem-resistant constriction was abolished by SNX-482, a blocker of R-type VDCCs. In contrast, diltiazem completely dilated freshly isolated arteries or arteries organ cultured in the absence of oxyHb, and SNX-482 was without effect. Consistent with functional observations, mRNA encoding R-type VDCCs (CaV 2.3) was detected in arteries organ cultured for 5 days in the presence but not in the absence of oxyHb. These observations suggest that cerebral arteries typically contain L-type VDCCs, but prolonged exposure (5 days) to oxyHb can induce R-type VDCC expression that may contribute to cerebral artery constriction. Further, we report that L-type VDCCs become less sensitive to diltiazem after 5-day exposure to oxyHb.
The present work is consistent with our recent observations of the emergence of R-type VDCCs in small diameter cerebral arteries of a rabbit SAH model 5 days after the intracisternal injection of whole blood.10 In cerebral arteries from SAH rabbits, R-type VDCC expression was associated with enhanced VDCC membrane currents and increased constriction at physiological intravascular pressures.10 The present study suggests oxyHb, a major blood component, is the causative agent leading to the emergence of R-type VDCCs in cerebral artery myocytes after SAH. OxyHb-induced expression of R-type VDCCs would promote increased Ca2+ entry and enhanced constriction of cerebral arteries. We estimate, based on our present and past studies, that R-type VDCC expression caused by SAH or oxyHb is responsible for approximately 20% of the constriction in response to elevated extracellular K+ or increased intravascular pressure. Considering flow through a cylinder is a function of the radius to the fourth power (Poiseuille Law), we believe R-type VDCC expression could have a substantial impact on cerebral blood flow after SAH. It is interesting to note that dilations to SNX-482 were slightly larger in the absence of diltiazem compared to in the presence of diltiazem in arteries organ cultured for 5 days in the presence of oxyHb (Figure 3). Considering that SNX-482 had little, if any, effect in freshly isolated arteries or arteries organ cultured in the absence of oxyHb, it is unlikely that 200 µmol/L SNX-482 is blocking L-type VDCCs. However, it is possible that the high concentration of diltiazem used in the present study (1mmol/L) may be influencing R-type VDCC activity or that there may be some unknown interaction between R-type and L-type VDCCs.
Numerous reports have provided evidence suggesting oxyHb plays a role in the development of SAH-induced vasospasm.6,8,18,19 An action commonly attributed to oxyHb is vasoconstriction occurring shortly on exposure of this agent to cerebral arteries in vitro.3,4,9,20 Several mechanisms have been proposed to contribute to this acute oxyHb-induced contraction including KV channel suppression,3,5 inhibition of Ca2+ sparks,4 elevated intracellular Ca2+ levels,8,20,21 increased Ca2+ sensitivity of the contractile apparatus attributable to increased activity of Rho kinase or protein kinase C,9,22 decreased availability of nitric oxide,23 and increased synthesis of the vasoconstrictor 20-HETE.24 In the present study, arteries were organ cultured with oxyHb however, oxyHb was not included in the physiological saline solution used during functional assessment after the organ culture period. Thus, our present findings suggest that in addition to the acute effects detailed above, long-term (5 days) oxyHb can impact cerebral artery function via changes in VDCC expression. It should be noted that the observed changes in Cav 2.3 expression cannot be simply attributed to the organ culture conditions used in the present study. Firstly, a large body of previous work supports the approach of organ culturing intact artery segments in serum-free media.11,25–28 Secondly, in the present study, cerebral arteries organ cultured in the absence of oxyHb exhibit properties comparable to freshly isolated arteries (eg, Figures 1 and 2
). Although organ culture conditions clearly do not exactly replicate in vivo conditions, we believe the approach used in the current study has allowed us to examine whether oxyHb can induce Cav 2.3 expression in contractile cerebral artery myocytes. Considering that multiple cell types are present in intact cerebral arteries, it is, however, possible that cells other than vascular smooth muscle may contribute to the observed increase in CaV 2.3 mRNA levels after 5-day oxyHb exposure. Although we cannot definitively rule out this possibility, functional data within this article support the notion that expression of CaV 2.3 occurs primarily in cerebral artery myocytes after oxyHb exposure.
At present, the signaling pathway linking oxyHb to CaV 2.3 expression in cerebral arteries is unclear. However, reactive oxygen species (ROS) produced during the oxidation of oxyHb can regulate gene expression29 and may play a role in the pathogenesis of cerebral vasospasm.23 Further, Peiro et al30 have demonstrated that glycosylated human oxyHb leads to the activation of 2 transcription factors, nuclear factor-
B (NFB) and activator protein 1 (AP-1), in cultured human aortic smooth muscle via redox-sensitive pathways. Interestingly, activated NFB has also been detected in cerebral cortices of a mouse SAH model in wild-type but not superoxide dismutase–overexpressing mice.31 Additionally, oxyHb-induced elevations in [Ca2+]i could lead to the activation of Ca2+-dependent transcription factors such as cyclic-AMP–dependent response element binding protein (CREB)32,33 and nuclear factor of activated T-cells (N-FAT).34 Future studies are needed to determine the transcriptional events associated with oxyHb-induced R-type VDCC expression.
In addition to enhanced expression of R-type VDCCs, 5-day exposure to oxyHb caused a decrease in the sensitivity of cerebral arteries to the L-type VDCC antagonist diltiazem. The IC50 value of diltiazem to reverse K+-induced constriction was 10-fold higher in arteries organ cultured for 5 days in the presence, compared to the absence, of oxyHb (Figure 1). This action of oxyHb is similar to the decreased functional response to L-type VDCC blockers reported by others after SAH35,36 or oxyHb incubation.37 We have also demonstrated that VDCC membrane currents obtained from cerebral artery myocytes isolated from 5-day SAH rabbits were less sensitive to diltiazem and nisoldipine.10 These findings may help to explain why L-type VDCC antagonists are potent dilators of arteries from healthy individuals yet exhibit only modest efficacy in the improvement of clinical outcome in SAH patients.
In summary, here we have demonstrated that oxyHb can induce R-type VDCC gene expression and decrease the sensitivity of cerebral arteries to the L-type VDCC antagonist diltiazem. We propose that oxyHb-induced changes in VDCCs are likely to play an important role in diameter regulation in cerebral arteries after SAH.
|
Acknowledgments |
|---|
The authors thank Hemosol Inc for their gracious gift of the purified oxyhemoglobin used in this study. The authors also thank Drs Masanori Ishiguro and Masayo Koide for their helpful comments on this study.
Sources of Funding
This work was supported by the Totman Medical Research Trust Fund, the Peter Martin Brain Aneurysm Endowment, the American Heart Association (SDG # 003029N), and the NIH (NCRR, P20 RR16435 and NHLBI, R01 HL078983).
Disclosures
None.
Received October 30, 2007; accepted November 22, 2007.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
1. Pluta RM, Afshar JK, Boock RJ, Oldfield EH. Temporal changes in perivascular concentrations of oxyhemoglobin, deoxyhemoglobin, and methemoglobin after subarachnoid hemorrhage. J Neurosurg. 1998; 88: 557–561.[Medline] [Order article via Infotrieve]
2. Mayberg MR, Okada T, Bark DH. The role of hemoglobin in arterial narrowing after subarachnoid hemorrhage. J Neurosurg. 1990; 72: 634–640.[Medline] [Order article via Infotrieve]
3. Ishiguro M, Morielli AD, Zvarova K, Tranmer BI, Penar PL, Wellman GC. Oxyhemoglobin-induced suppression of voltage-dependent K+ channels in cerebral arteries by enhanced tyrosine kinase activity. Circ Res. 2006; 99: 1252–1260.
4. Jewell RP, Saundry CM, Bonev AD, Tranmer BI, Wellman GC. Inhibition of Ca++ sparks by oxyhemoglobin in rabbit cerebral arteries. J Neurosurg. 2004; 100: 295–302.[Medline] [Order article via Infotrieve]
5. Koide M, Penar PL, Tranmer BI, Wellman GC. Heparin-binding EGF-like growth factor mediates oxyhemoglobin-induced suppression of voltage-dependent potassium channels in rabbit cerebral artery myocytes. Am J Physiol Heart Circ Physiol. 2007; 293: H1750–H1759.
6. Nishizawa S, Laher I. Signaling mechanisms in cerebral vasospasm. Trends Cardiovasc Med. 2005; 15: 24–34.[CrossRef][Medline] [Order article via Infotrieve]
7. Takenaka K, Yamada H, Sakai N, Ando T, Nakashima T, Nishimura Y, Okano Y, Nozawa Y. Cytosolic calcium changes in cultured rat aortic smooth-muscle cells induced by oxyhemoglobin. J Neurosurg. 1991; 74: 620–624.[Medline] [Order article via Infotrieve]
8. Wellman GC. Ion channels and calcium signaling in cerebral arteries following subarachnoid hemorrhage. Neurol Res. 2006; 28: 690–702.[CrossRef][Medline] [Order article via Infotrieve]
9. Wickman G, Lan C, Vollrath B. Functional roles of the rho/rho kinase pathway and protein kinase C in the regulation of cerebrovascular constriction mediated by hemoglobin: relevance to subarachnoid hemorrhage and vasospasm. Circ Res. 2003; 92: 809–816.
10. Ishiguro M, Wellman TL, Honda A, Russell SR, Tranmer BI, Wellman GC. Emergence of a R-type Ca2+ channel (CaV 2.3) contributes to cerebral artery constriction after subarachnoid hemorrhage. Circ Res. 2005; 96: 419–426.
11. Ishiguro M, Puryear CB, Bisson E, Saundry CM, Nathan DJ, Russell SR, Tranmer BI, Wellman GC. Enhanced myogenic tone in cerebral arteries from a rabbit model of subarachnoid hemorrhage. Am J Physiol Heart Circ Physiol. 2002; 283: H2217–H2225.
12. Knot HJ, Nelson MT. Regulation of arterial diameter and wall [Ca2+] in cerebral arteries of rat by membrane potential and intravascular pressure. J Physiol (Lond). 1998; 508: 199–209.
13. Nelson MT, Patlak JB, Worley JF, Standen NB. Calcium channels, potassium channels, and voltage dependence of arterial smooth muscle tone. Am J Physiol. 1990; 259: C3–C18.[Medline] [Order article via Infotrieve]
14. Earley S, Waldron BJ, Brayden JE. Critical role for transient receptor potential channel TRPM4 in myogenic constriction of cerebral arteries. Circ Res. 2004; 95: 922–929.
15. Striessnig J, Grabner M, Mitterdorfer J, Hering S, Sinnegger MJ, Glossmann H. Structural basis of drug binding to L Ca2+ channels. Trends Pharmacol Sci. 1998; 19: 108–115.[CrossRef][Medline] [Order article via Infotrieve]
16. Newcomb R, Szoke B, Palma A, Wang G, Chen X, Hopkins W, Cong R, Miller J, Urge L, Tarczy-Hornoch K, Loo JA, Dooley DJ, Nadasdi L, Tsien RW, Lemos J, Miljanich G. Selective peptide antagonist of the class E calcium channel from the venom of the tarantula Hysterocrates gigas. Biochemistry. 1998; 37: 15353–15362.[CrossRef][Medline] [Order article via Infotrieve]
17. Wellman GC, Bonev AD, Nelson MT, Brayden JE. Gender differences in coronary artery diameter involve estrogen, nitric oxide, and Ca2+-dependent K+ channels. Circ Res. 1996; 79: 1024–1030.
18. Dietrich HH, Dacey RG Jr. Molecular keys to the problems of cerebral vasospasm. Neurosurgery. 2000; 46: 517–530.[Medline] [Order article via Infotrieve]
19. Laher I, Zhang JH. Protein kinase C and cerebral vasospasm. J Cereb Blood Flow Metab. 2001; 21: 887–906.[CrossRef][Medline] [Order article via Infotrieve]
20. Macdonald RL, Weir BK. A review of hemoglobin and the pathogenesis of cerebral vasospasm. Stroke. 1991; 22: 971–982.
21. Vollrath BA, Weir BK, Macdonald RL, Cook DA. Intracellular mechanisms involved in the responses of cerebrovascular smooth-muscle cells to hemoglobin. J Neurosurg. 1994; 80: 261–268.[Medline] [Order article via Infotrieve]
22. Lan C, Das D, Wloskowicz A, Vollrath B. Endothelin-1 modulates hemoglobin-mediated signaling in cerebrovascular smooth muscle via RhoA/Rho kinase and protein kinase C. Am J Physiol Heart Circ Physiol. 2004; 286: H165–H173.
23. Pluta RM. Delayed cerebral vasospasm and nitric oxide: review, new hypothesis, and proposed treatment. Pharmacol Ther. 2005; 105: 23–56.[CrossRef][Medline] [Order article via Infotrieve]
24. Takeuchi K, Miyata N, Renic M, Harder DR, Roman RJ. Hemoglobin, NO, and 20-HETE interactions in mediating cerebral vasoconstriction following SAH. Am J Physiol Regul Integr Comp Physiol. 2006; 290: R84–R89.
25. Kleppisch T, Winter B, Nelson MT. ATP-sensitive potassium channels in cultured arterial segments. Am J Physiol. 1996; 271: H2462–H2468.[Medline] [Order article via Infotrieve]
26. Reading SA, Earley S, Waldron BJ, Welsh DG, Brayden JE. TRPC3 mediates pyrimidine receptor-induced depolarization of cerebral arteries. Am J Physiol Heart Circ Physiol. 2005; 288: H2055–H2061.
27. Welsh DG, Morielli AD, Nelson MT, Brayden JE. Transient receptor potential channels regulate myogenic tone of resistance arteries. Circ Res. 2002; 90: 248–250.
28. Zeidan A, Nordstrom I, Dreja K, Malmqvist U, Hellstrand P. Stretch-dependent modulation of contractility and growth in smooth muscle of rat portal vein. Circ Res. 2000; 87: 228–234.
29. Liu H, Colavitti R, Rovira II, Finkel T. Redox-dependent transcriptional regulation. Circ Res. 2005; 97: 967–974.
30. Peiro C, Matesanz N, Nevado J, Lafuente N, Cercas E, Azcutia V, Vallejo S, Rodriguez-Manas L, Sanchez-Ferrer CF. Glycosylated human oxyhaemoglobin activates nuclear factor-kappaB and activator protein-1 in cultured human aortic smooth muscle. Br J Pharmacol. 2003; 140: 681–690.[CrossRef][Medline] [Order article via Infotrieve]
31. Saito A, Kamii H, Kato I, Takasawa S, Kondo T, Chan PH, Okamoto H, Yoshimoto T. Transgenic CuZn-superoxide dismutase inhibits NO synthase induction in experimental subarachnoid hemorrhage. Stroke. 2001; 32: 1652–1657.
32. Pulver RA, Rose-Curtis P, Roe MW, Wellman GC, Lounsbury KM. Store-operated Ca2+ entry activates the CREB transcription factor in vascular smooth muscle. Circ Res. 2004; 94: 1351–1358.
33. Wellman GC, Cartin L, Eckman DM, Stevenson AS, Saundry CM, Lederer WJ, Nelson MT. Membrane depolarization, elevated Ca2+ entry, and gene expression in cerebral arteries of hypertensive rats. Am J Physiol Heart Circ Physiol. 2001; 281: H2559–H2567.
34. Stevenson AS, Gomez MF, Hill-Eubanks DC, Nelson MT. NFAT4 movement in native smooth muscle. A role for differential Ca2+ signaling. J Biol Chem. 2001; 276: 15018–15024.
35. Sahlin C, Owman C, Chang JY, Delgado T, Salford LG, Svendgaard NA. Changes in contractile response and effect of a calcium antagonist, nimodipine, in isolated intracranial arteries of baboon following experimental subarachnoid hemorrhage. Brain Res Bull. 1990; 24: 355–361.[CrossRef][Medline] [Order article via Infotrieve]
36. Yoshida K, Nakamura S, Umezawa T, Nakano M, Tsubokawa T. Effect of diltiazem and thromboxane A2 synthetase inhibitor (OKY-046) on vessels following experimental subarachnoid hemorrhage. Surg Neurol. 1990; 34: 309–317.[CrossRef][Medline] [Order article via Infotrieve]
37. Yoshimoto Y, Kim P, Sasaki T, Kirino T, Takakura K. Functional changes in cultured strips of canine cerebral arteries after prolonged exposure to oxyhemoglobin. J Neurosurg. 1995; 83: 867–874.[Medline] [Order article via Infotrieve]
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||